List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7086735/publications.pdf Version: 2024-02-01



#	Article	IF	Citations
1	Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. Clinical Cancer Research, 2022, 28, 298-307.	7.0	12
2	CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden. Future Oncology, 2022, , .	2.4	4
3	Managing Metastatic Melanoma in 2022: A Clinical Review. JCO Oncology Practice, 2022, 18, 335-351.	2.9	91
4	The "Great Debate―at Immunotherapy Bridge 2021, December 1st–2nd, 2021. Journal of Translational Medicine, 2022, 20, 179.	4.4	0
5	The "Great Debate―at Melanoma Bridge 2021, December 2nd–4th, 2021. Journal of Translational Medicine, 2022, 20, 200.	4.4	0
6	Abstract CT218: First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors. Cancer Research, 2022, 82, CT218-CT218.	0.9	0
7	Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. Clinical Cancer Research, 2021, 27, 87-95.	7.0	72
8	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge―(December 4th–5th,)	Tj ETQq0 (4.4) 0 ₃ rgBT /Ove
9	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	2.8	57
10	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 3317-3328.	7.0	14
11	Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. Clinical Cancer Research, 2021, 27, 4195-4204.	7.0	18
12	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. European Journal of Cancer, 2021, 145, 1-10.	2.8	17
13	Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma. Cancer Discovery, 2021, 11, 1996-2013.	9.4	32
14	T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 1402.	12.8	85

15	The "Great Debate―at Immunotherapy Bridge 2020, December 3rd, 2020. Journal of Translational Medicine, 2021, 19, 144.	4.4	0
16	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro-Oncology, 2021, 23, 1961-1973.	1.2	66

17	The "Great Debate―at Melanoma Bridge 2020: December, 5th, 2020. Journal of Translational Medicine, 2021, 19, 142.	4.4	1

18Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors.. Journal of
Clinical Oncology, 2021, 39, 2568-2568.1.61

#	Article	IF	CITATIONS
19	Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. , 2021, 9, e002553.		24

Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd \hat{a} \in 3rd,) Tj ETQq0 0.0 rgBT /Overlock 10 \pm 10 Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd \hat{a} \in 3rd,) Tj ETQq0 0.0 rgBT /Overlock 10 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm 20 \pm

21	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
22	Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. , 2021, 9, e002835.		11
23	Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma. Frontiers in Oncology, 2021, 11, 728113.	2.8	1
24	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. Journal of Clinical Oncology, 2021, 39, 2914-2925.	1.6	55
25	Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2021, 19, 64-72.	0.1	4
26	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncology, The, 2021, 22, 1692-1704.	10.7	129
27	Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapy. American Journal of Cancer Research, 2021, 11, 5190-5213.	1.4	0
28	Intratumoral Immunotherapy—Update 2019. Oncologist, 2020, 25, e423-e438.	3.7	92
29	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. JAMA Oncology, 2020, 6, 1256.	7.1	38
30	The Great Debate at â€~Immunotherapy Bridge', Naples, December 5, 2019. , 2020, 8, e000921.		3
31	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. British Journal of Cancer, 2020, 123, 1590-1598.	6.4	57
32	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 5598-5608.	7.0	13
33	Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). Melanoma Management, 2020, 7, MMT41.	0.5	3
34	COVID-19 and Cancer: a Comprehensive Review. Current Oncology Reports, 2020, 22, 53.	4.0	220
35	<p>Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab</p> . OncoTargets and Therapy, 2020, Volume 13, 4021-4034.	2.0	5
	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse		

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adver events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604.

98

#	Article	IF	CITATIONS
37	lpilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. , 2020, 8, e000331.		66
38	Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> V600-Mutant Non-Melanoma Cancers. Cancer Discovery, 2020, 10, 657-663.	9.4	93
39	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutant Melanoma. Clinical Cancer Research, 2020, 26, 46-53.	7.0	32
40	Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTEâ€028 study. Cancer, 2020, 126, 3021-3030.	4.1	97
41	Anti-IL6R role in treatment of COVID-19-related ARDS. Journal of Translational Medicine, 2020, 18, 165.	4.4	82
42	The Great Debate at "Melanoma Bridgeâ€; Naples, December 7th, 2019. Journal of Translational Medicine, 2020, 18, 171.	4.4	2
43	Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi) Journal of Clinical Oncology, 2020, 38, 10029-10029.	1.6	1
44	Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study Journal of Clinical Oncology, 2020, 38, 5080-5080.	1.6	1
45	Cardivascular Toxicities of Immunotherapy. , 2020, , 259-276.		Ο
46	Identifying strategies to address obstacles to optimal integration of cancer immunotherapies in the community Journal of Clinical Oncology, 2020, 38, 96-96.	1.6	5
47	The great debate at "Immunotherapy Bridge 2018â€; Naples, November 29th, 2018. , 2019, 7, 221.		4
48	Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2019, 3, 1-9.	3.0	31
49	The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugs. JAMA Dermatology, 2019, 155, 862.	4.1	1
50	Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. British Journal of Cancer, 2019, 121, 417-420.	6.4	24
51	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. Case Reports in Oncology, 2019, 12, 260-276.	0.7	63
52	Toxicities in Immune Checkpoint Inhibitors. , 2019, , 205-226.		2
53	Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncolmmunology, 2019, 8, e1524695.	4.6	44
54	Abstract 4062: Activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125)		4

as monotherapy in patients with refractory solid tumors: a phase lb study (ILLUMINATE-101). , 2019, , .

#	Article	IF	CITATIONS
55	A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma Journal of Clinical Oncology, 2019, 37, 9586-9586.	1.6	6
56	Oncologist uptake of comprehensive genomic profile guided targeted therapy. Oncotarget, 2019, 10, 4616-4629.	1.8	13
57	Cardiovascular Toxicities Related to Immune Checkpoint Inhibitors. , 2019, , .		0
58	Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM Journal of Clinical Oncology, 2019, 37, 9524-9524.	1.6	3
59	Abstract CT093: Axitinib in combination with pembrolizumab (AXI+PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers. , 2019, , .		Ο
60	Abstract 4057: Measurement of myeloid derived suppressor cells (MDSC), T regulatory cells (Treg), CD8+and CD4+T-cells, and cytokines/chemokines in patients with metastatic melanoma treated with pembrolizumab and propranolol. , 2019, , .		0
61	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncology, The, 2018, 19, 405-415.	10.7	305
62	Oncolytic Viruses: T-VEC and Others. , 2018, , 387-403.		1
63	The Great Debate at "Melanoma Bridgeâ€, Napoli, December 2nd, 2017. Journal of Translational Medicine, 2018, 16, 101.	4.4	3
64	Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Circulation: Heart Failure, 2018, 11, e004408.	3.9	34
65	Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. Journal of Molecular Diagnostics, 2018, 20, 95-109.	2.8	50
66	Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. British Journal of Clinical Pharmacology, 2018, 84, 112-121.	2.4	8
67	Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. JAMA Oncology, 2018, 4, 384.	7.1	280
68	Circulating T-Cell Biomarkers to Predict Response to Immune Checkpoint Inhibitors. Journal of the American College of Surgeons, 2018, 227, e56.	0.5	0
69	BRAF Inhibition in <i>BRAF</i> ^{V600} -Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology, 2018, 36, 3477-3484.	1.6	247
70	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1714-1768.	1.6	2,691
71	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. Journal of Clinical Oncology, 2018, 36, 1658-1667.	1.6	483
72	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> ^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2018, 2, 1-9.	3.0	20

#	Article	IF	CITATIONS
73	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nature Communications, 2018, 9, 3600.	12.8	96
74	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. Journal of Pain and Symptom Management, 2018, 56, 460-472.	1.2	14
75	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj	ETQq1 1 0.7	84314 rgBT
76	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. , 2018, 6, 32.		111
77	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. New England Journal of Medicine, 2018, 379, 722-730.	27.0	983
78	Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 742-774.	4.9	202
79	A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma Journal of Clinical Oncology, 2018, 36, 9515-9515.	1.6	22
80	Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN-α2b in locally/regionally advanced melanoma Journal of Clinical Oncology, 2018, 36, 181-181.	1.6	8
81	Comprehensive immune and mutational profile of melanoma Journal of Clinical Oncology, 2018, 36, 182-182.	1.6	1
82	Immune deserts: Correlation of low CD8 gene expression with non-response to checkpoint inhibition Journal of Clinical Oncology, 2018, 36, 23-23.	1.6	1
83	Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC) Journal of Clinical Oncology, 2018, 36, 579-579.	1.6	10
84	A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057) Journal of Clinical Oncology, 2018, 36, TPS219-TPS219.	1.6	4
85	Effect of CTLA-4 overexpression on response to ipilimumab in melanoma Journal of Clinical Oncology, 2018, 36, 190-190.	1.6	1
86	Correlation of lung cancer mutational profile with immune profile Journal of Clinical Oncology, 2018, 36, 146-146.	1.6	1
87	Trial in progress: A phase 2 study of intratumor pil-12 plus electroporation in combination with intravenous pembrolizumab in patients with stage III/IV mealanoma progressing on either pembrolizumab or nivolumab treatment (PISCES) Journal of Clinical Oncology, 2018, 36, TPS9601-TPS9601.	1.6	0
88	Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. , 2017, 5, 1.		68
89	Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 3601-3609.	7.0	58
90	Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. Journal of Immunotherapy, 2017, 40, 31-35.	2.4	85

IGOR PUZANOV

#	Article	IF	CITATIONS
91	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		111
92	Challenges faced when identifying patients for combination immunotherapy. Future Oncology, 2017, 13, 1607-1618.	2.4	10
93	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell, 2017, 170, 1109-1119.e10.	28.9	1,124
94	A firstâ€inâ€human phase I, multicenter, openâ€label, doseâ€escalation study of the oral RAF/VEGFRâ€2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from <scp>BRAF</scp> mutation status. Cancer Medicine, 2017, 6, 1904-1914.	2.8	24
95	Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Research, 2017, 27, 585-590.	1.2	21
96	A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. Journal of Neuro-Oncology, 2017, 133, 435-442.	2.9	9
97	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European Journal of Cancer, 2017, 86, 37-45.	2.8	183
98	BRAF ^{V600} mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study. OncoTargets and Therapy, 2017, Volume 10, 965-971.	2.0	28
99	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. Journal of Translational Medicine, 2017, 15, 223.	4.4	25
100	Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. , 2017, 5, 72.		37
101	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Journal of Clinical Oncology, 2017, 35, 2535-2541.	1.6	383
102	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study Journal of Clinical Oncology, 2017, 35, 2004-2004.	1.6	1
103	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with <i>BRAF</i> ^{V600} mutation Journal of Clinical Oncology, 2017, 35, 9074-9074.	1.6	10
104	Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204 Journal of Clinical Oncology, 2017, 35, 9507-9507.	1.6	106
105	Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma Journal of Clinical Oncology, 2017, 35, 9509-9509.	1.6	27
106	Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma Journal of Clinical Oncology, 2017, 35, 9566-9566.	1.6	5
107	A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors Journal of Clinical Oncology, 2017, 35, e14040-e14040.	1.6	12
108	Abstract 2123: Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells. , 2017, , .		0

#	Article	IF	CITATIONS
109	Abstract 588: Advanced molecular characterization of severe autoimmune toxicities associated with checkpoint inhibitor therapies. , 2017, , .		0
110	Comparative analysis of the <i><scp>GNAQ</scp></i> , <i><scp>GNA</scp>11</i> , <i><scp>SF</scp>3B1</i> , and <i><scp>EIF</scp>1<scp>AX</scp></i> driver mutations in melanoma and across the cancer spectrum. Pigment Cell and Melanoma Research, 2016, 29, 470-473.	3.3	18
111	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. Cancer Immunology Research, 2016, 4, 569-573.	3.4	20
112	Responses to immune checkpoint inhibitors in nonagenarians. Oncolmmunology, 2016, 5, e1234572.	4.6	24
113	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 304-313.e6.	1.9	11
114	Pembrolizumab for the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 867-873.	0.8	10
115	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. European Journal of Cancer, 2016, 67, 46-54.	2.8	77
116	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunology Research, 2016, 4, 959-967.	3.4	428
117	A phase <scp>II</scp> trial of erlotinib and bevacizumab for patients with metastatic melanoma. Pigment Cell and Melanoma Research, 2016, 29, 101-103.	3.3	11
118	The efficacy of antiâ€₽Dâ€1 agents in acral and mucosal melanoma. Cancer, 2016, 122, 3354-3362.	4.1	236
119	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nature Communications, 2016, 7, 10582.	12.8	412
120	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. , 2016, 4, 60.		60
121	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine, 2016, 375, 1749-1755.	27.0	1,668
122	Treatment of elderly patients with melanoma. Memo - Magazine of European Medical Oncology, 2016, 9, 13-16.	0.5	0
123	Talimogene laherparepvec in advanced melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 781-788.	0.8	0
124	Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. Journal of Clinical Oncology, 2016, 34, 2619-2626.	1.6	449
125	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Annals of Surgical Oncology, 2016, 23, 4169-4177.	1.5	236
126	Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. Journal of Clinical Oncology, 2016, 34, 871-878.	1.6	266

#	Article	IF	CITATIONS
127	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncology, The, 2016, 17, 378-388.	10.7	327
128	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2016, 2, 234.	7.1	534
129	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq1 1 0.78	4314 rgB 13.7	「/Overlock 1 529
130	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti–PD-1 Therapy. Cancer Immunology Research, 2016, 4, 474-480.	3.4	17
131	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. Blood, 2016, 128, 480-480.	1.4	5
132	Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1 Journal of Clinical Oncology, 2016, 34, 105-105.	1.6	16
133	Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study Journal of Clinical Oncology, 2016, 34, 5581-5581.	1.6	22
134	KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy Journal of Clinical Oncology, 2016, 34, 9513-9513.	1.6	8
135	Clinical activity of anti- <i>programmed death-1</i> (PD-1) agents in acral and mucosal melanoma Journal of Clinical Oncology, 2016, 34, 9516-9516.	1.6	1
136	Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma Journal of Clinical Oncology, 2016, 34, 9568-9568.	1.6	76
137	A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265) Journal of Clinical Oncology, 2016, 34, TPS9598-TPS9598.	1.6	6
138	Thyroid nodule: not as clear-cut as it seems. Journal of Community and Supportive Oncology, 2016, 14, 45-48.	0.1	0
139	Comprehensive echocardiographic assessment of cardiac function in patients with metastatic renal cell carcinoma newly initiated on sunitinib Journal of Clinical Oncology, 2016, 34, e16072-e16072.	1.6	0
140	Risk of left ventricular systolic dysfunction with sunitinib therapy in patients with metastatic renal cell carcinoma: A prospective cohort study Journal of Clinical Oncology, 2016, 34, e16104-e16104.	1.6	0
141	Anti-PD-1 in patients with advanced malignancies and baseline organ dysfunction Journal of Clinical Oncology, 2016, 34, e14539-e14539.	1.6	0
142	Cyclooxygenase inhibition and response to anti-PD1/L1 in advanced melanoma Journal of Clinical Oncology, 2016, 34, e21023-e21023.	1.6	0
143	Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell and Melanoma Research, 2015, 28, 611-612.	3.3	125
144	Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Anti-Cancer Drugs, 2015, 26, 785-792.	1.4	2

#	Article	IF	CITATIONS
145	Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer, 2015, 51, 1435-1443.	2.8	61
146	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2015, 33, 2780-2788.	1.6	1,988
147	A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 701-711.	7.0	86
148	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. New England Journal of Medicine, 2015, 373, 428-437.	27.0	438
149	Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunology Research, 2015, 3, 464-469.	3.4	91
150	Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy, 2015, 7, 611-619.	2.0	141
151	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, The, 2015, 16, 908-918.	10.7	1,419
152	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. Journal of Clinical Oncology, 2015, 33, 2013-2020.	1.6	385
153	Treatment of NRAS-Mutant Melanoma. Current Treatment Options in Oncology, 2015, 16, 15.	3.0	110
154	Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). Journal of Translational Medicine, 2015, 13, K8.	4.4	28
155	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. British Journal of Cancer, 2015, 113, 1571-1580.	6.4	88
156	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. New England Journal of Medicine, 2015, 373, 726-736.	27.0	1,483
157	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clinical Cancer Research, 2015, 21, 5215-5221.	7.0	17
158	Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy. Expert Review of Anticancer Therapy, 2015, 15, 1389-1403.	2.4	102
159	Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 159-168.	2.6	49
160	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. Blood, 2015, 126, 4263-4263.	1.4	9
161	Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL) Journal of Clinical On <u>cology, 2015, 33, 3012-3012.</u>	1.6	18
162	Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma Journal of Clinical Oncology, 2015, 33, 3068-3068.	1.6	4

#	Article	IF	CITATIONS
163	Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN) Journal of Clinical Oncology, 2015, 33, 4507-4507.	1.6	11
164	Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial Journal of Clinical Oncology, 2015, 33, 4508-4508.	1.6	5
165	Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders Journal of Clinical Oncology, 2015, 33, 9019-9019.	1.6	11
166	Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma Journal of Clinical Oncology, 2015, 33, 9020-9020.	1.6	15
167	Updated overall survival (OS) results for BRF113220, a phase l–II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with <i>BRAF</i> V600 metastatic melanoma (MM) Journal of Clinical Oncology, 2015, 33, 9036-9036.	1.6	12
168	Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL) Journal of Clinical Oncology, 2015, 33, 9040-9040.	1.6	2
169	Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma Journal of Clinical Oncology, 2015, 33, 9063-9063.	1.6	23
170	Early change in lactate dehydrogenase is marker of response to PD-1/PDL1 inhibitors Journal of Clinical Oncology, 2015, 33, e20045-e20045.	1.6	1
171	A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma Journal of Clinical Oncology, 2015, 33, TPS9081-TPS9081.	1.6	9
172	LK or IGF1R: When selectivity hurts. Aging, 2015, 7, 342-343.	3.1	0
173	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer, 2014, 120, 2684-2693.	4.1	105
174	Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma. JAMA - Journal of the American Medical Association, 2014, 312, 1744.	7.4	312
175	Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. , 2014, 2, 2.		42
176	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. Oncologist, 2014, 19, 616-622.	3.7	94
177	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncology, The, 2014, 15, 954-965.	10.7	225
178	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology, 2014, 32, 1020-1030.	1.6	2,015
179	Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). , 2014, 2, .		16
180	Management of â€~pan-negative' melanoma: current and emerging strategies. Melanoma Management, 2014, 1, 87-90.	0.5	0

#	Article	IF	CITATIONS
181	A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS) Journal of Clinical Oncology, 2014, 32, 10503-10503.	1.6	8
182	Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM) Journal of Clinical Oncology, 2014, 32, 2511-2511.	1.6	41
183	VE-BASKET, a first-in-kind, phase II, histology-independent "basket―study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m) Journal of Clinical Oncology, 2014, 32, 2533-2533.	1.6	12
184	Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial Journal of Clinical Oncology, 2014, 32, 9002-9002.	1.6	64
185	Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma Journal of Clinical Oncology, 2014, 32, 9006-9006.	1.6	3
186	Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma Journal of Clinical Oncology, 2014, 32, 9008a-9008a.	1.6	26
187	Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with <i>BRAF</i> V600 mutation-positive (+) metastatic melanoma (MM) Journal of Clinical Oncology, 2014, 32, 9010-9010.	1.6	13
188	Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase III trial in patients with stage IIIb-IV melanoma Journal of Clinical Oncology, 2014, 32, 9026-9026.	1.6	5
189	Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma Journal of Clinical Oncology, 2014, 32, 9029-9029.	1.6	43
190	Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 <i>BRAF</i> mutations other than V600E Journal of Clinical Oncology, 2014, 32, 9075-9075.	1.6	1
191	Infectious Colitis Associated With Ipilimumab Therapy. Gastroenterology Research, 2014, 7, 28-31.	1.3	14
192	Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel Journal of Clinical Oncology, 2014, 32, 11089-11089.	1.6	1
193	A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2014, 32, 4570-4570.	1.6	Ο
194	Î ³ -H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000). Clinical Cancer Research, 2013, 19, 721-730.	7.0	52
195	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. Expert Review of Dermatology, 2013, 8, 479-487.	0.3	4
196	Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 1767-1774.	1.6	335
197	BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition. Clinical Cancer Research, 2013, 19, 6696-6702.	7.0	160
198	A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma. Journal of Immunotherapy, 2013, 36, 490-495.	2.4	25

#	Article	IF	CITATIONS
199	Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) Journal of Clinical Oncology, 2013, 31, CRA9006-CRA9006.	1.6	16
200	Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608 Journal of Clinical Oncology, 2013, 31, CRA9007-CRA9007.	1.6	8
201	OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma Journal of Clinical Oncology, 2013, 31, LBA9008-LBA9008.	1.6	21
202	Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) Journal of Clinical Oncology, 2013, 31, CRA9006-CRA9006.	1.6	41
203	Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608 Journal of Clinical Oncology, 2013, 31, CRA9007-CRA9007.	1.6	23
204	OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma Journal of Clinical Oncology, 2013, 31, LBA9008-LBA9008.	1.6	67
205	Abstract C85: Drug interaction study of tivantinib in cancer subjects using a cocktail approach , 2013, , .		0
206	Is Renal Thrombotic Angiopathy an Emerging Problem in the Treatment of Ovarian Cancer Recurrences?. Oncologist, 2012, 17, 1534-1540.	3.7	25
207	Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 3414-3427.	7.0	30
208	Marked, Homogeneous, and Early [¹⁸ F]Fluorodeoxyglucose–Positron Emission Tomography Responses to Vemurafenib in <i>BRAF</i> -Mutant Advanced Melanoma. Journal of Clinical Oncology, 2012, 30, 1628-1634.	1.6	172
209	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. New England Journal of Medicine, 2012, 367, 1694-1703.	27.0	2,445
210	Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib. New England Journal of Medicine, 2012, 366, 707-714.	27.0	1,955
211	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncology, The, 2012, 13, 459-465.	10.7	995
212	<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. New England Journal of Medicine, 2012, 366, 207-215.	27.0	978
213	Dabrafenib in patients with Val600Clu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2012, 13, 1087-1095.	10.7	841
214	Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors. Memo - Magazine of European Medical Oncology, 2012, 5, 302-308.	0.5	0
215	Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factorâ€ŧargeted therapy. Cancer, 2012, 118, 6055-6062.	4.1	41
216	Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncology, 2012, 8, 509-523.	2.4	22

#	Article	IF	CITATIONS
217	Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study Journal of Clinical Oncology, 2012, 30, 4117-4117.	1.6	14
218	Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2012, 30, 4506-4506.	1.6	7
219	Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study Journal of Clinical Oncology, 2012, 30, 4545-4545.	1.6	4
220	BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) Journal of Clinical Oncology, 2012, 30, 8501-8501.	1.6	24
221	Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (CSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (CSK1120212) in patients with BRAFi-naive metastatic melanoma Journal of Clinical Oncology, 2012, 30, 8510-8510.	1.6	41
222	Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study Journal of Clinical Oncology, 2012, 30, 8519-8519.	1.6	14
223	Biological challenges of BRAF inhibitor therapy. Molecular Oncology, 2011, 5, 116-123.	4.6	30
224	Insulinâ€like growth factorâ€1 receptor inhibitor, AMGâ€479, in cetuximabâ€refractory head and neck squamous cell carcinoma. Head and Neck, 2011, 33, 1804-1808.	2.0	16
225	Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 3794-3802.	7.0	49
226	B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma. Current Oncology Reports, 2010, 12, 146-152.	4.0	49
227	Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochemical Pharmacology, 2010, 80, 638-646.	4.4	16
228	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467, 596-599.	27.8	1,610
229	A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets. Clinical Cancer Research, 2010, 16, 348-357.	7.0	36
230	Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 809-819.	27.0	3,288
231	Targeted Molecular Therapy in Melanoma. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 196-201.	1.6	45
232	Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1. Journal of Clinical Oncology, 2009, 27, 5800-5807.	1.6	293
233	Combination targeted therapy in advanced renal cell carcinoma. Cancer, 2009, 115, 2368-2375.	4.1	45
234	Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Immunotherapy, 2009, 32, 181-185.	2.4	48

#	Article	IF	CITATIONS
235	Determination of chemically reduced pyrrolobenzodiazepine SJGâ€136 in human plasma by HPLCâ€MS/MS: application to an anticancer phase I dose escalation study. Journal of Mass Spectrometry, 2008, 43, 42-52.	1.6	9
236	Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group. Journal of Clinical Oncology, 2008, 26, 2178-2185.	1.6	238
237	Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib. Oncologist, 2008, 13, 1001-1011.	3.7	315
238	Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer. Clinical Cancer Research, 2007, 13, 764s-769s.	7.0	107
239	Molecular Targets in Melanoma from Angiogenesis to Apoptosis. Clinical Cancer Research, 2006, 12, 2376s-2383s.	7.0	46